Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | EML4 - ALK MDM2 amp TP53 wild-type |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
EML4 - ALK MDM2 amp TP53 wild-type | lung adenocarcinoma | sensitive | Milademetan + Trametinib | Preclinical - Pdx | Actionable | In a preclinical study, the combination of Mekinist (trametinib) and Milademetan resulted in increased tumor growth inhibition compared to either therapy alone in a patient-derived xenograft model of lung adenocarcinoma harboring wild-type TP53, EML4-ALK, and MDM2 amplification (PMID: 37182602). | 37182602 |